NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

minimized bone removal and increased fusion potential compared to a posterolateral cylindrical-threaded single-implant system. Expansion of SCS Systems Into the PDN Market: Nevro’s focus on ...

The company launched the full market release of HFX iQ with HFX AdaptivAI, a responsive and personalized pain management platform that powers the HFX iQ spinal cord stimulation (SCS) system. In ...

Nevro's comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device ... personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system in November 2024.

95.5% of Nevro shares are held by institutional ... which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the ...